A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo PaolettiCristina Oliva, Stephen Rubin, Steven Stein, Charles E Geyer

Research output: Contribution to journalArticlepeer-review

Abstract

Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported.
Original languageEnglish
Pages (from-to)533-43
Number of pages11
JournalBreast cancer research and treatment
Volume112
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses'. Together they form a unique fingerprint.

Cite this